D
11.40
-0.21 (-1.81%)
| Previous Close | 11.61 |
| Open | 11.60 |
| Volume | 521,987 |
| Avg. Volume (3M) | 676,752 |
| Market Cap | 397,018,656 |
| Price / Earnings (Forward) | 112.36 |
| Price / Sales | 5.42 |
| Price / Book | 3.44 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 |
| Profit Margin | -26.38% |
| Operating Margin (TTM) | 3.24% |
| Diluted EPS (TTM) | -0.450 |
| Quarterly Revenue Growth (YOY) | 530.30% |
| Total Debt/Equity (MRQ) | 1.27% |
| Current Ratio (MRQ) | 15.95 |
| Operating Cash Flow (TTM) | -6.89 M |
| Levered Free Cash Flow (TTM) | -7.11 M |
| Return on Assets (TTM) | -1.51% |
| Return on Equity (TTM) | -28.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Delcath Systems, Inc. | Bullish | Bullish |
AIStockmoo Score
2.0
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 2.73% |
| % Held by Institutions | 45.84% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 31.00 (HC Wainwright & Co., 171.93%) | Buy |
| Median | 28.00 (145.61%) | |
| Low | 25.00 (Stephens & Co., 119.30%) | Buy |
| Average | 28.00 (145.61%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 11.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Aug 2025 | 31.00 (171.93%) | Buy | 10.19 |
| Stephens & Co. | 23 Jun 2025 | 25.00 (119.30%) | Buy | 13.26 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Sep 2025 | Announcement | Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 21 Aug 2025 | Announcement | Delcath Systems to Participate in Upcoming Investor Conferences |
| 19 Aug 2025 | Announcement | Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer |
| 06 Aug 2025 | Announcement | Delcath Systems Reports Second Quarter 2025 Results and Business Highlights |
| 29 Jul 2025 | Announcement | Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference |
| 25 Jul 2025 | Announcement | Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 23 Jul 2025 | Announcement | Delcath Systems to Host Second Quarter 2025 Earnings Call |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |